Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effects of Escitalopram on Climacteric Vasomotor Symptoms

View through CrossRef
Abstract Vasomotor symptoms (VMS) are episodes of profuse heat accompanied by sweating and flushing. experienced predominantly around the head, neck, chest, and upper back. VMS are often considered the cardinal symptoms of menopause, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. To evaluate the effectiveness of escitalopram for attenuating the vasomotor symptoms. This prospective, observational study was conducted in Department of Pharmacology and Therapeuties, North East Medical College, Sylhet in collaboration with Outpatient Department of Psychiatry, Sylhet M.A.G Osmani Medical College Hospital, Sylhet, among 50 women (ages 40 to 62 years) who were postmenopausal women. Women were assigned to receive escitalopram 10 to 20 mg/d for 8 weeks. Primary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8. Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement (defined as hot flash frequency 50% decrease from baseline). All information was recorded in data collection sheet. Data was processed and analyzed with the help of computer program SPSS and Microsoft excel. The study found that escitalopram resulted in a significant reduction in the frequency. severity, and bothersomeness of hot flashes. At baseline, the mean frequency of hot flashes for all subjects was 9.75 per day. At 8 weeks, the mean daily frequency decreased to 5.18. Sixty two percent of the patients reported >=50% decreases in hot flash frequency. Treatment response was rapid, showing some improvement in hot flash frequency and severity within 1 week of starting treatment. Present study concluded that treatment with the selective serotonin reuptake inhibitor (SSRI) escitalopram significantly reduces the frequency and severity of vasomotor symptoms compared with placebo. Key Words: Vasomotor Symptoms, Escitalopram.
Title: Effects of Escitalopram on Climacteric Vasomotor Symptoms
Description:
Abstract Vasomotor symptoms (VMS) are episodes of profuse heat accompanied by sweating and flushing.
experienced predominantly around the head, neck, chest, and upper back.
VMS are often considered the cardinal symptoms of menopause, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder.
To evaluate the effectiveness of escitalopram for attenuating the vasomotor symptoms.
This prospective, observational study was conducted in Department of Pharmacology and Therapeuties, North East Medical College, Sylhet in collaboration with Outpatient Department of Psychiatry, Sylhet M.
A.
G Osmani Medical College Hospital, Sylhet, among 50 women (ages 40 to 62 years) who were postmenopausal women.
Women were assigned to receive escitalopram 10 to 20 mg/d for 8 weeks.
Primary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8.
Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement (defined as hot flash frequency 50% decrease from baseline).
All information was recorded in data collection sheet.
Data was processed and analyzed with the help of computer program SPSS and Microsoft excel.
The study found that escitalopram resulted in a significant reduction in the frequency.
severity, and bothersomeness of hot flashes.
At baseline, the mean frequency of hot flashes for all subjects was 9.
75 per day.
At 8 weeks, the mean daily frequency decreased to 5.
18.
Sixty two percent of the patients reported >=50% decreases in hot flash frequency.
Treatment response was rapid, showing some improvement in hot flash frequency and severity within 1 week of starting treatment.
Present study concluded that treatment with the selective serotonin reuptake inhibitor (SSRI) escitalopram significantly reduces the frequency and severity of vasomotor symptoms compared with placebo.
Key Words: Vasomotor Symptoms, Escitalopram.

Related Results

Regulation of climacteric fruit ripening in melon: recent advances and future challenges
Regulation of climacteric fruit ripening in melon: recent advances and future challenges
Abstract Fruit ripening is a complex and highly regulated process where tomato and strawberry have been the model species classically used for studying climacteric a...
Rise of escitalopram and the fall of citalopram
Rise of escitalopram and the fall of citalopram
Abstract Introduction Citalopram and escitalopram are among the most used medications and are key treatments for many psychiatr...
Flax Seed and Climacteric Symptoms – A Review
Flax Seed and Climacteric Symptoms – A Review
BACKGROUND Universally every woman faces menopause and feeling of onset of uncomfortable physical, psychological and emotional changes. Many fear about their loss of beauty and sex...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
CLIMATE AND MENOPAUSE
CLIMATE AND MENOPAUSE
Introduction: Climacteric and menopause is defined by the World Health Organization as a biological phase of a woman’s life and not a pathological process. have the most severe sym...
Male-female comparison of vasomotor effects of circulating hormones in human intracranial arteries
Male-female comparison of vasomotor effects of circulating hormones in human intracranial arteries
Abstract Background The purpose of this study was to examine whether there are sex differences in vasomotor responses and receptor localization of h...
Proprietary Delivery System of a Novel Supplement Reduced Vasomotor Symptoms in Menopausal Women
Proprietary Delivery System of a Novel Supplement Reduced Vasomotor Symptoms in Menopausal Women
Objective: To evaluate a supplement system for the reduction of vasomotor symptoms in menopausal women. Methods: A prospective, open-label, IRB-approved study was conducted over 12...
MON-005 AN UNUSUAL CASE OF VASOMOTOR SYMPTOMS IN A POST-MENOPAUSAL WOMAN
MON-005 AN UNUSUAL CASE OF VASOMOTOR SYMPTOMS IN A POST-MENOPAUSAL WOMAN
Abstract Disclosure: R. Akhter: None. W. Akhter: None. A. Zaidi: None. J.L. Gilden: Novartis Pharmaceuticals. Introduction: Hot flashes are amon...

Back to Top